Publications

Phase 2 data may support atezolizumab plus chemotherapy as a treatment option in advanced or recurrent thymic carcinoma.

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

The new drug application for TLX007-CDx has been approved by the FDA for patients with prostate cancer.

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Christina Henson, MD, discusses recent phase 3 trial results comparing durvalumab to cetuximab in head and neck cancer, and why the trial was stopped early.

Timely guideline-concordant care may mitigate racial and ethnic disparities in overall survival among patients with inflammatory breast cancer.